Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Papadopoulos

Showing results (211-220 of 288) with videos related to

Pageof 29
Sort By:
Cancer Chemotherapy and Pharmacology|August 27, 2013
A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumorsKyriakos P Papadopoulos, Howard A Burris, Michael Gordon, et al.
BMJ Oncology|January 31, 2025
First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumoursAung Naing, Kyriakos P Papadopoulos, Michael J Pishvaian, et al.
Bone Marrow Transplantation|July 27, 2005
Pilot study of tandem high-dose chemotherapy and autologous stem cell transplantation with a novel combination of regimens in patients with poor risk lymphomaK P Papadopoulos, W Noguera-Irizarry, L Wiebe, et al.
Journal of Neuro-Oncology|January 5, 2000
A phase I study of high-dose BCNU, etoposide and escalating-dose thiotepa (BTE) with hematopoietic progenitor cell support in adults with recurrent and high-risk brain tumorsK P Papadopoulos, C Balmaceda, M Fetell, et al.
Cancer Chemotherapy and Pharmacology|October 16, 2012
Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancerK N Chi, A Tolcher, P Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumorsAlejandro D Ricart, Jordan D Berlin, Kyriakos P Papadopoulos, et al.
Cancer Chemotherapy and Pharmacology|November 25, 2014
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myelomaAnthony W Tolcher, Amita Patnaik, Kyriakos P Papadopoulos, et al.
Cancer Chemotherapy and Pharmacology|July 10, 2016
Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumoursAmita Patnaik, Anthony Tolcher, Kyriakos P Papadopoulos, et al.
European Journal of Cancer (Oxford, England : 1990)|November 26, 2023
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohortEric Jonasch, Todd M Bauer, Kyriakos P Papadopoulos, et al.
Cancer Chemotherapy and Pharmacology|July 18, 2018
Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancerAmita Patnaik, Michael Gordon, Frank Tsai, et al.
Pageof 29

Showing results (211-220 of 288) with videos related to

Sort By:
Pageof 29
Cancer Chemotherapy and Pharmacology|August 27, 2013
A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumorsKyriakos P Papadopoulos, Howard A Burris, Michael Gordon, et al.
BMJ Oncology|January 31, 2025
First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumoursAung Naing, Kyriakos P Papadopoulos, Michael J Pishvaian, et al.
Bone Marrow Transplantation|July 27, 2005
Pilot study of tandem high-dose chemotherapy and autologous stem cell transplantation with a novel combination of regimens in patients with poor risk lymphomaK P Papadopoulos, W Noguera-Irizarry, L Wiebe, et al.
Journal of Neuro-Oncology|January 5, 2000
A phase I study of high-dose BCNU, etoposide and escalating-dose thiotepa (BTE) with hematopoietic progenitor cell support in adults with recurrent and high-risk brain tumorsK P Papadopoulos, C Balmaceda, M Fetell, et al.
Cancer Chemotherapy and Pharmacology|October 16, 2012
Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancerK N Chi, A Tolcher, P Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumorsAlejandro D Ricart, Jordan D Berlin, Kyriakos P Papadopoulos, et al.
Cancer Chemotherapy and Pharmacology|November 25, 2014
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myelomaAnthony W Tolcher, Amita Patnaik, Kyriakos P Papadopoulos, et al.
Cancer Chemotherapy and Pharmacology|July 10, 2016
Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumoursAmita Patnaik, Anthony Tolcher, Kyriakos P Papadopoulos, et al.
European Journal of Cancer (Oxford, England : 1990)|November 26, 2023
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohortEric Jonasch, Todd M Bauer, Kyriakos P Papadopoulos, et al.
Cancer Chemotherapy and Pharmacology|July 18, 2018
Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancerAmita Patnaik, Michael Gordon, Frank Tsai, et al.
Pageof 29